Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Go back to Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis| (NASDAQ: AUPH) | Delayed: 16.07 -0.01 (0.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.08 | 52 Week High | $5.69 | |||
| Open | $15.98 | 52 Week Low | $1.42 | |||
| Day High | $16.38 | P/E | N/A | |||
| Day Low | $15.93 | EPS | $0.00 | |||
| Volume | 970,278 | |||||
